Retinoblastoma-protein-dependent cell-cycle inhibition by the tumour suppressor p16
The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.
Abstract
D-type cyclins, in association with the cyclin-dependent kinases Cdk4 or Cdk6, promote progression through the G1 phase of the cell cycle by phosphorylating the retinoblastoma protein (RB). The activities of Cdk4 and Cdk6 are constrained by inhibitors such as p16, the product of the CDKN2 gene on human chromosome 9p21 (refs 12-14). The frequent deletion or mutation of CDKN2 in tumour cells suggests that p16 acts as a tumour suppressor. We show that wild-type p16 arrests normal diploid cells in late G1, whereas a tumour-associated mutant of p16 does not. Significantly, the ability of p16 to induce cell-cycle arrest is lost in cells lacking functional RB, including primary fibroblasts from Rb-/- mouse embryos. Thus, loss of p16, overexpression of D-cyclins and loss of RB have similar effects on G1 progression, and may represent a common pathway to tumorigenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, cells lacking functional RB were resistant to p16INK4a-mediated cell cycle arrest, implying that the ability of CDK4 (and later, CDK6) to drive G1 phase progression required RB (33-35) and predicting that chemical CDK4/6 inhibitors would show efficacy only if RB were functionally intact.”
From Targeting CDK4 and CDK6: From Discovery to Therapy (2016) · cites this paper as [33]
Citations
Cites
A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.
Serrano, M., Hannon, G. J., & Beach, D. (1993) · Nature · doi:10.1038/366704a0 · Cited by 3,650
A cell cycle regulator potentially involved in genesis of many tumor types
Kamb, A., Gruis, N. A., Weaver-Feldhaus, J., Liu, Q., Harshman, K., Tavtigian, S. V., Stockert, E., Day, R. S., Johnson, B. E., & Skolnick, M. H. (1994) · Science · doi:10.1126/science.8153634 · Cited by 2,751
G1 phase progression: Cycling on cue
Sherr, C. J. (1994) · Cell · doi:10.1016/0092-8674(94)90540-1 · Cited by 2,674
Cyclins and cancer II: Cyclin D and CDK inhibitors come of age
Hunter, T., & Pines, J. (1994) · Cell · doi:10.1016/0092-8674(94)90543-6 · Cited by 2,091
pl5INK4B is a potentia| effector of TGF-β-induced cell cycle arrest
Hannon, G. J., & Beach, D. (1994) · Nature · doi:10.1038/371257a0 · Cited by 1,950
Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers
Nobori, T., Miura, K., Wu, D. J., Lois, A., Takabayashi, K., & Carson, D. A. (1994) · Nature · doi:10.1038/368753a0 · Cited by 1,742
Cyclin D1 is a nuclear protein required for cell cycle progression in G1
Baldin, V, Lukas, J., Marcote, M. J., Pagano, M., & Draetta, G. (1993) · Genes & Development · doi:10.1101/gad.7.5.812 · Cited by 1,614
Self-citation(1993) · Genes & Development · doi:10.1101/gad.7.3.331 · Cited by 1,264
Distinct Roles for Cyclin-Dependent Kinases in Cell Cycle Control
van den Heuvel, S., & Harlow, E. (1993) · Science · doi:10.1126/science.8266103 · Cited by 1,092
Overexpression of mouse D-type cyclins accelerates G1 phase in rodent fibroblasts.
Quelle, D. E., Ashmun, R. A., Shurtleff, S. A., Kato, J. Y., Bar-Sagi, D., Roussel, M. F., & Sherr, C. J. (1993) · Genes & Development · doi:10.1101/gad.7.8.1559 · Cited by 1,032
Research works printed but not linked: 8
- Jiang, W. et al. Oncogene 8, 3447–3457 (1993).
- Lukas, J., Pagano, M., Staskova, Z., Draetta, G. & Bartek, J. Oncogene 9, 707–718 (1994).
- Jen, J. et al. Cancer Res. 54, 6353–6358 (1994).
- Li, Y., Nichols, M. A., Shay, J. W. & Xiong, Y. Cancer Res. 54, 6078–6082 (1994).
- Otterson, G. A., Kratzke, R. A., Coxon, A., Kim, Y. W. & Kaye, F. J. Oncogene 9, 3375–3378 (1994).
- Tam, S. W. Shay, J. W. & Pagano, M. Cancer Res. 54, 5816–5820 (1994).
- Ohta, M. et al. Cancer Res. 54, 5269–5272 (1994).
- Lukas, J. et al. Oncogene (in the press).
Cited by
Items 501–600 of 902
Gene bi-targeting by viral and human miRNAs
Veksler‐Lublinsky, I., Shemer‐Avni, Y., Kedem, K., & Ziv-Ukelson, M. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-249 · Cited by 32
“CDKN2A (also known as p16-INK4A) is a tumor suppressor that binds to the complex of cyclin D1 and cyclindependent kinase 4 to repress its ability to phosphorylate the retinoblastoma protein, and consequently, blocks cell cycle progression from G1 to S [67, 68 ].”
BackgroundVarma, H., Skildum, A. J., & Conrad, S. E. (2007) · PLoS ONE · doi:10.1371/journal.pone.0001256 · Cited by 30
“). These results are consistent with a model in which the only requirement of cdk4 in MCF-7 cell proliferation is to inactivate pRb family members”
ResultGene Methylation in Breast Ductal Fluid from BRCA1 and BRCA2 Mutation Carriers
Antill, Y. C., Mitchell, G., Johnson, S. A. S., Devereux, L. M., Milner, A. D., Iulio, J. D., Lindeman, G. J., Kirk, J., Phillips, K. A., & Campbell, I. (2010) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0359 · Cited by 30
“The cyclin-dependent kinase inhibitor 2A (p16) plays an integral role in cell cycle progression through the G1 phase of cell cycling via its inhibition of Rb phosphorylation (12, 26).”
BackgroundNoh, S. J., Li, Y., Xiong, Y., & Guan, K. (1999) · PubMed · Cited by 30
Tzai, T., Tsai, Y., & Chow, N.-H. (2004) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/s1078-1439(03)00176-5 · Cited by 30
Dissecting the Senescence-like Program in Tumor Cells Activated by Ras Signaling
Bihani, T., Chicas, A., Lo, C. P.-K., & Lin, A. W. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608127200 · Cited by 32
Relationship between Ras pathways and cell cycle control
Ewen, M. E. (2000) · Springer eBooks · doi:10.1007/978-1-4615-4253-7_1 · Cited by 37
Beilstein, M. C., & Silberg, D. G. (2002) · Gastroenterology Clinics of North America · doi:10.1016/s0889-8553(02)00013-4 · Cited by 30
Choi, Y. J., Sáez, B., Anders, L., Hydbring, P., Stefano, J., Bacon, N. A., Cook, C., Kalaszczyńska, I., Signoretti, S., Young, R. A., et al. (2014) · Developmental Cell · doi:10.1016/j.devcel.2014.06.015 · Cited by 33
“This notion is supported by overwhelming evidence revealing that germline ablation of D-cyclins, or knockdown of D-cyclins in cancer cells, ectopic expression of cyclin D-Cdk4/6 inhibitor p16, or treatment of cells with a chemical inhibitor of cyclin D-associated kinase, all resulted in cell-cycle arrest (Fry et al.,…”
BackgroundZhao, W., Huang, C., Otterson, G. A., Leon, M. E., Tang, Y., Shilo, K., & Villalona, M. A. (2012) · Journal of Oncology · doi:10.1155/2012/957437 · Cited by 29
Al‐Khalaf, H. H., & Aboussekhra, A. (2016) · Molecular Carcinogenesis · doi:10.1002/mc.22564 · Cited by 32
Lai, H., Sun, C., Yu, M., Chen, H., Liu, H.-S., & Chu, T. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19991222)84:6<545::aid-ijc1>3.0.co;2-2 · Cited by 89
Obeyesekere, M. N., Knudsen, E. S., Wang, J. Y. J., & Zimmerman, S. O. (1997) · Cell Proliferation · doi:10.1111/j.1365-2184.1997.tb00933.x · Cited by 32
Mechanisms That Limit the In Vitro Proliferative Potential of Human CD8+ T Lymphocytes
Migliaccio, M., Raj, K., Menzel, O., & Rufer, N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.6.3335 · Cited by 29
Correlation of Levels and Patterns of Genomic Instability With Histological Grading of DCIS
Ellsworth, R. E., Ellsworth, D. L., Love, B., Patney, H. L., Hoffman, L. R., Kane, J. L., Hooke, J. A., & Shriver, C. D. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-007-9459-8 · Cited by 29
“Underexpression of RB1 has been correlated with high-grade invasive breast carcinomas and increased cellular proliferation.25 Another tumor suppressor gene, cyclin-dependent kinase inhibitor 2A (TP16) on chromosome 9p21, is also involved in cell cycle control and loss of the ability of p16 to induce cell cycle arrest…”
BackgroundNishiwaki, E., Turner, S. L., Harju-Baker, S., Miyazaki, S., Kashiwagi, M., Koh, J., & Serizawa, H. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7726-7734.2000 · Cited by 35
“Despite the facts that p16 and p15 have significant homology in their primary structures and that both inhibit phosphorylation of pRb by CDK4 and CDK6, genetic studies suggest that only mutations of p16 closely correlate with human cancer (15, 16, 19, 20, 22, 31, 38, 39).”
BackgroundInfluentialCause-specific telomere factors deregulation in hepatocellular carcinoma
Idrissi, M. E., Hervieu, V., Merle, P., Mortreux, F., & Wattel, E. (2013) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-32-64 · Cited by 28
Aberrant expression of p16 and RB protein in eccrine porocarcinoma
Gu, L., Ichiki, Y., & Kitajima, Y. (2002) · Journal of Cutaneous Pathology · doi:10.1034/j.1600-0560.2002.290805.x · Cited by 28
Fujiwara, S., Noguchi, T., Takeno, S., Kimura, Y., Fumoto, S., & Kawahara, K. (2007) · Diseases of the Esophagus · doi:10.1111/j.1442-2050.2007.00735.x · Cited by 30
Expression ofp16INK4and Retinoblastoma ProteinRbin Vulvar Lesions of Chinese Women
Chan, M. K. M., Cheung, T. H., Chung, T. K. H., Bao, S. Y., Zhao, C. L., Nobori, T., & Wong, Y. F. (1998) · Gynecologic Oncology · doi:10.1006/gyno.1997.4914 · Cited by 31
Tumor Suppressor Genes in Prostate Cancer
Bookstein, R. (2001) · Humana Press eBooks · doi:10.1007/978-1-59259-009-4_5 · Cited by 33
Cascalló, M., Mercadé, E., Capellá, G., Lluı́s, F., Fillat, C., Gómez-Foix, A. M., & Mazo, A. (1999) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7700070 · Cited by 28
Bai, J., Chen, J., Ma, M., Cai, M., Xu, F., Wang, G., Tao, K., & Shuai, X. (2014) · DNA and Cell Biology · doi:10.1089/dna.2014.2340 · Cited by 33
“Tumor suppressor gene p16, encoded by the CDKN2A lo-cus, is an inhibitor of cyclin-dependent kinase 4 (CDK4) and 6 (CDK6), which bind cyclin D1 and phosphorylate the retinoblastoma protein (Rb) tumor suppressor genes (Lukas et al. , 1995).”
Wang, H., Wang, X., Xu, L., Zhang, J., & Cao, H. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.551160 · Cited by 31
“CDKN2A is a driver tumor suppressor gene, which regulates cell cycle progress by cyclin-dependent kinases CDK4 and CDK6 (25).”
BackgroundInfluentialCDK Inhibitors as Sensitizing Agents for Cancer Chemotherapy
Gupta, P., Narayanan, S., & Yang, D. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-816435-8.00009-2 · Cited by 36
Lange, S., Richard, D., Viergutz, T., Kriehuber, R., Weiss, D. G., & Simkó, M. (2002) · Radiation and Environmental Biophysics · doi:10.1007/s00411-002-0145-8 · Cited by 28
“This generally causes cells to accumulate in G 1 and prevents them from entering S-phase [ 37 ].”
BackgroundDamo, L. A., Snyder, P. W., & Franklin, D. S. (2004) · Molecular Carcinogenesis · doi:10.1002/mc.20068 · Cited by 31
Methylation analysis of the cell cycle control genes in myelofibrosis with myeloid metaplasia
Kumagai, T., Tefferi, A., Jones, L. C., & Koeffler, H. P. (2005) · Leukemia Research · doi:10.1016/j.leukres.2004.11.002 · Cited by 27
Lamperska, K. M., Karezewska, A., Kwiatkowska, E., & Mackiewicz, A. A. (2002) · Acta Biochimica Polonica · doi:10.18388/abp.2002_3795 · Cited by 29
“One of the regulatory proteins is p16, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6 (Sherr, 1996). p16 by binding to CDKs complexes inhibits their ability to interact with cyclin D (Lukas et al., 1995).”
BackgroundLi, F., Liu, J., Mayne, R., & Wu, C. (1997) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(97)00089-x · Cited by 27
Sawicka, M., Pawlikowski, J. S., Wilson, S., Ferdinando, D. P., Wu, H. G., Adams, P. D., Gunn, D. A., & Parish, W. E. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053313 · Cited by 26
“Whilst some reports have located p16INK4a predominately to the cytoplasm of a range of cell lines [4,19], two reports located p16INK4a predominantly to the nucleus of the WI-38 fibroblast cell line [3,20].”
BackgroundXia, L., Zhang, W., & Gao, L. (2019) · Biomarkers · doi:10.1080/1354750x.2019.1652685 · Cited by 26
“Mapped to human chromosome 9p21, TSG p16 gene is known as the cyclin-dependent kinase inhibitor 2A (CDKN2A) (Lukas et al. 1995).”
BackgroundGurushankar, K., Rimac, H., Potemkin, V., & Grishina, M. (2021) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.129925 · Cited by 27
Francis, S. M., Bergsied, J., Isaac, C. E., Coschi, C. H., Martens, A. L., Hojilla, C. V., Chakrabarti, S., DiMattia, G. E., Khoka, R., Wang, J. Y. J., et al. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00473-09 · Cited by 31
The role of Ink4a/Arf in ErbB2 mammary gland tumorigenesis.
D’Amico, M., Wu, K., Vizio, D. D., Reutens, A. T., Stahl, M. C., Fu, M., Albanese, C., Russell, R. G., Muller, W. J., White, M. A., et al. (2003) · PubMed · Cited by 28
Cao, Z., Wei, L., Zhu, W., & Yao, X. (2018) · Medicine · doi:10.1097/md.0000000000010182 · Cited by 26
“are encoded by the cyclin-dependent kinase inhibitor 2A (CDKN2A) and play a key role in cell cycle regulation.([13,14]) As a common TSG, downregulation or loss of CDKN2A (p16 and p14) expression through DNAmethylation frequently occurs”
BackgroundCharacterization of novel LncRNA P14AS as a protector of ANRIL through AUF1 binding in human cells
Ma, W., Qiao, J., Zhou, J., Gu, L., & Deng, D. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01150-4 · Cited by 25
Ubiquitin-specific protease 28: the decipherment of its dual roles in cancer development
Ren, X., Jiang, M., Ding, P., Zhang, X., Zhou, X. J., Shen, J., Liu, D., Yan, X., & Ma, Z. (2023) · Experimental Hematology and Oncology · doi:10.1186/s40164-023-00389-z · Cited by 26
Rinaldi, A., Mensah, A. A., Kwee, I., Forconi, F., Orlandi, E. M., Lucioni, M., Gattei, V., Marasca, R., Berger, F., Cogliatti, S., et al. (2013) · British Journal of Haematology · doi:10.1111/bjh.12515 · Cited by 26
Expression of cyclin D1a and D1b as predictive factors for treatment response in colorectal cancer
Myklebust, M. P., Li, Z., Tran, T., Rui, H., Knudsen, E. S., Elsaleh, H., Fluge, Ø., Vonen, B., Myrvold, H. E., Leh, S. M., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.463 · Cited by 26
“Phosphorylation of pRb by cyclin D facilitates the expression of cyclin E, a positive regulator of the G1 checkpoint (Lukas et al, 1995; Ohtsubo et al, 1995; Vidal and Koff, 2000).”
BackgroundNijman, S. M. B., Hijmans, E. M., Messaoudi, S. E., van Dongen, M. M. W., Sardet, C., & Bernards, R. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602312200 · Cited by 28
Keblusek, P., Dorsman, J. C., Teunisse, A. F. A. S., Teunissen, H., van der Eb, A. J., & ZANTEMA, A. (1999) · Journal of General Virology · doi:10.1099/0022-1317-80-2-381 · Cited by 29
“These results are in agreement with the facts that cell-cycle inhibition by p16INK%A is pRbdependent (Lukas et al., 1995 ; Medema et al., 1995) and that pRb is inactivated in Ad5E1-transformed cells by binding to E1A (Nevins, 1992).”
BackgroundResultInfluentialGrowth Factors in Lens Development
Lang, R. A., & McAvoy, J. W. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.012 · Cited by 30
Chao, H. H., Buchmann, A. M., & DeCaprio, J. A. (2000) · Molecular and Cellular Biology · doi:10.1128/mcb.20.20.7624-7633.2000 · Cited by 28
G1/S regulatory mechanisms from yeast to man
Reed, S. I. (1996) · Springer eBooks · doi:10.1007/978-1-4615-5873-6_2 · Cited by 27
Zhu, Z. Y., Song, H., & Xu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.641077 · Cited by 28
“Previous study indicated that CDKN2Amainly regulate cell cycle progression by interacting with CDK4 and inhibit the function of retinoblastoma protein, thereby arresting the cell cycle at the G1/ S phase (23, 37, 38).”
BackgroundDecreased number of p16-positive senescent cells in human endometrium as a marker of miscarriage
Parvanov, D. A., Ganeva, R., Vidolova, N., & Stamenov, G. (2021) · Journal of Assisted Reproduction and Genetics · doi:10.1007/s10815-021-02182-5 · Cited by 29
“In addition, p16 is considered to be a tumour suppressor gene that inhibits cell proliferation arresting the cell cycle in the G1-phase [3, 4].”
BackgroundPhospho-T356RB1 predicts survival in HPV-negative squamous cell carcinoma of the head and neck
Beck, T. N., Kaczmar, J. M., Handorf, E. A., Nikonova, A. S., Dubyk, C. W., Peri, S., Lango, M. N., Ridge, J. A., Serebriiskii, I. G., Burtness, B. A., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.4321 · Cited by 25
Abnormal expression of Rb pathway–related proteins in salivary gland acinic cell carcinoma
LIU, T., ZHU, E., WANG, L., Okada, T., YAMAGUCHI, A., & OKADA, N. (2005) · Human Pathology · doi:10.1016/j.humpath.2005.06.014 · Cited by 25
Bourgo, R. J., Braden, W. A., Wells, S. I., & Knudsen, E. S. (2008) · Molecular Carcinogenesis · doi:10.1002/mc.20456 · Cited by 27
Prognostic role of methylated GSTP1, p16, ESR1 and PITX2 in patients with breast cancer
Sheng, X., Guo, Y., & Yang, L. (2017) · Medicine · doi:10.1097/md.0000000000007476 · Cited by 24
Gristina, V., Mantia, M. L., Galvano, A., Cutaia, S., Barraco, N., Castiglia, M., Perez, A., Bono, M., Iacono, F., Greco, M., et al. (2021) · Journal of Molecular Pathology · doi:10.3390/jmp2020016 · Cited by 24
“Beyond 40% of NSCLC, cases express loss of PTEN and it is related to poor prognosis, especially for EGFR-positive patients treated with EGFR-TKIs [103].”
BackgroundYang, V. W. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-809954-4.00008-6 · Cited by 27
Saegusa, M., Hashimura, M., Kuwata, T., 浜野, 美., & Okayasu, I. (2006) · International Journal of Cancer · doi:10.1002/ijc.22112 · Cited by 24
Miyakoshi, J., Kitagawa, K., Yamagishi, N., Ohtsu, S., Day, R. S., & Takebe, H. (1997) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1997.tb00298.x · Cited by 24
NMR structural characterization of the CDK inhibitor p19INK4d
Kalus, W., Baumgartner, R., Renner, C., Noegel, A. A., Chan, F. K. M., Winoto, A., & Holak, T. A. (1997) · FEBS Letters · doi:10.1016/s0014-5793(96)01465-2 · Cited by 30
p16/CDKN2 alterations and pRb expression in oesophageal squamous carcinoma.
Busatto, G., Shiao, Y., Parenti, A., Baffa, R., Ruol, A., Plebani, M., & Rugge, M. (1998) · Molecular Pathology · doi:10.1136/mp.51.2.80 · Cited by 24
Loss of p16 and/or pRb protein expression in NSCLC
Chen, J., Chen, Y., Chen, C.-Y., & Wang, Y. (2001) · Lung Cancer · doi:10.1016/s0169-5002(00)00191-4 · Cited by 24
Wang, L., Zhan, X., Shen, X., Li, M., Yang, J., Yu, W., Chen, H., Jin, B., & Mao, Z. (2018) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-018-3281-4 · Cited by 23
Ashizawa, S., Nishizawa, H., Yamada, M., Higashi, H., Kondo, T., Ozawa, H., Kakita, A., & Hatakeyama, M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m007992200 · Cited by 26
p16ink4aGene and Hematological Malignancies
Quesnel, B., Preudhomme, C., & Fenaux, P. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609051724 · Cited by 25
Castellano, M., Gabrielli, B. G., Hussussian, C. J., Dracopoli, N. C., & Hayward, N. K. (1997) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12276538 · Cited by 23
Duncan, M. K., Cvekl, A., Kantorow, M., & Piatigorsky, J. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.006 · Cited by 32
Velasco, J. A., Feijoó, E., Avila, M. A., & Notario, V. (1998) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199803)21:3<177::aid-mc5>3.0.co;2-j · Cited by 4
Trzeciak, L., Hennig, E. E., Kolodziejski, J., Nowacki, M. P., & Ostrowski, J. (2001) · Cancer Letters · doi:10.1016/s0304-3835(00)00652-2 · Cited by 23
Advances in Sputum Analysis for Screening and Early Detection of Lung Cancer
Tockman, M. S. (2000) · Cancer Control · doi:10.1177/107327480000700101 · Cited by 23
Association between P16INK4a Promoter Methylation and HNSCC: A Meta-Analysis of 21 Published Studies
Shi, H., Chen, X., Lu, C. C., Gu, C., Jiang, H., Meng, R., Niu, X., Huang, Y., & Lü, M. (2015) · PLoS ONE · doi:10.1371/journal.pone.0122302 · Cited by 24
Correlation between DNA alterations and p53 and p16 protein expression in cancer cell lines
Murai, Y., Hayashi, S., Takahashi, H., Tsuneyama, K., & Takano, Y. (2005) · Pathology - Research and Practice · doi:10.1016/j.prp.2005.01.002 · Cited by 26
Pathological characterization of Kank in renal cell carcinoma
Roy, B. C., Aoyagi, T., Sarkar, S., Nomura, K., Kanda, H., Iwaya, K., Tachibana, M., & Kiyama, R. (2004) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2004.08.012 · Cited by 22
Jin, X., Lee, J.-S., Kwak, S., Jung, J.-E., Kim, T.-K., Xu, C., Hong, Z.-S., Li, Z., Kim, S.-M., Whang, K. Y., et al. (2006) · Molecules and Cells · doi:10.1016/s1016-8478(23)12881-0 · Cited by 22
p16 Controls p53 Protein Expression Through miR-dependent Destabilization of MDM2
Al‐Khalaf, H. H., & Aboussekhra, A. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0017 · Cited by 23
Calbó, J., Serna, C., Garriga, J., Graña, X., & Mazo, A. (2004) · Cell Death and Differentiation · doi:10.1038/sj.cdd.4401481 · Cited by 25
Hung, K.-S., Hong, C.-Y., Lee, J. J., Lin, S., Huang, S. C., Wang, T., Tse, V., Sliverberg, G. D., Weng, S.-C., & Hsiao, M. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.2339 · Cited by 24
Expression of the cyclin‐dependent kinase inhibitor p16 during the ongoing cell cycle
Soucek, T., Pusch, O., Hengstschläger-Ottnad, E., Wawra, E., BERNASCHEK, G., & Hengstschläger, M. (1995) · FEBS Letters · doi:10.1016/0014-5793(95)01033-b · Cited by 23
Lens Induction and Determination
Fisher, M. A., & Grainger, R. M. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.003 · Cited by 25
Precision medicine in Ewing sarcoma: a translational point of view
Gargallo, P., Juan, A. D., Yáñez, Y., Dolz, S., Segura, V., Castel, V., & Cañete, A. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02298-7 · Cited by 22
“Wildtype p16 (INK4) arrests normal diploid cells in late G1 (p16-dependent cell cycle arrest is lost in cells lacking functional RB protein) [143, 144].”
BackgroundMishra, R., & Das, B. R. (2003) · Molecular Biology Reports · doi:10.1023/a:1026384402585 · Cited by 22
Bassnett, S., & Beebe, D. C. (2004) · Cambridge University Press eBooks · doi:10.1017/cbo9780511529825.010 · Cited by 26
Sheaff, R. J., & Roberts, J. M. (1998) · Results and problems in cell differentiation · doi:10.1007/978-3-540-69686-5_1 · Cited by 22
Hypoxia Stimulates p16 Expression and Association with cdk4
Zygmunt, A., Tedesco, V. C., Udho, E. B., & Krucher, N. A. (2002) · Experimental Cell Research · doi:10.1006/excr.2002.5564 · Cited by 22
Nagasawa, M., Gelfand, E. W., & Lucas, J. J. (2001) · Oncogene · doi:10.1038/sj.onc.1204396 · Cited by 26
“However, it should be noted that these latter two studies were performed with the U2OS cell line, which is defective in production of the p16INK4a cdk inhibitor (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995), a trait which itself may have dramatic e ects on cdk regulation.”
BackgroundRegulation of Cellular Genes in a Chromosomal Context by the Retinoblastoma Tumor Suppressor Protein
Buchmann, A. M., Swaminathan, S., & Thimmapaya, B. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.8.4565 · Cited by 22
“It arrests cells in G1 when overexpressed; however, this arrest is dependent on the presence of wild-type pRb (30).”
BackgroundMolecular Genetics of Renal Cell Carcinoma
Erlandsson, R. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(97)00384-1 · Cited by 23
Takahashi, K. (2010) · Development Growth & Differentiation · doi:10.1111/j.1440-169x.2010.01169.x · Cited by 21
Targeting Rb inactivation in cancers by synthetic lethality.
Gordon, G. M., & Du, W. (2011) · PubMed · Cited by 24
Oral Cavity and Oropharyngeal Squamous Cell Carcinoma Genomics
Tan, M., Myers, J. N., & Agrawal, N. (2013) · Otolaryngologic Clinics of North America · doi:10.1016/j.otc.2013.04.001 · Cited by 20
Dissecting the Contribution of p16INK4A and the Rb Family to the Ras Transformed Phenotype
Mitchell, P. J., Pérez‐Nadales, E., Malcolm, D. S., & Lloyd, A. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.7.2530-2542.2003 · Cited by 23
“Until recently, it had been thought that Rb was responsible for mediating the growth-inhibitory effects of p16INK4A ( 40 , 44).”
BackgroundGene knockout and transgenic technologies in risk assessment: The next generation
Rosenberg, M. P. (1997) · Molecular Carcinogenesis · doi:10.1002/(sici)1098-2744(199711)20:3<288::aid-mc5>3.0.co;2-h · Cited by 20
Liu, H., Urabe, K., Moroi, Y., Yasumoto, S., Kokuba, H., Imafuku, S., Koga, T., Masuda, T., Aburatani, H., Furue, M., et al. (2006) · Journal of Cutaneous Pathology · doi:10.1111/j.1600-0560.2006.00438.x · Cited by 19
“The ectopic expression of p16 leads to the accumulation of pRb, resulting in sequestration of E2F and consequent G1 arrest.(18) If E7 directly inactivates pRb, hrHPV-infected cells would proliferate even in the presence of a very high level of p16.”
BackgroundWang, H., Tseng, Y., Wu, H., Chu, F., Kuo, Y., & Wang, S. (2014) · Natural Product Communications · doi:10.1177/1934578x1400900921 · Cited by 20
p16 gene overexpression in mouse bladder carcinomas
Asamoto, M., Hori, T., Baba‐Toriyama, H., Sano, M., Takahashi, S., Tsuda, H., & Shirai, T. (1998) · Cancer Letters · doi:10.1016/s0304-3835(97)00447-3 · Cited by 19
Oncoprotein BMI‐1 induces the malignant transformation of HaCaT cells
Wang, Q., Li, W., You, P., Su, J., Zhu, M.-H., Xie, D., Zhu, H., He, Z., Li, J., Ding, X., et al. (2008) · Journal of Cellular Biochemistry · doi:10.1002/jcb.21969 · Cited by 19
“…HaCaT-BMI-1 cells. p14ARF and p16INK4a are encoded by the INK4a-ARF locus mapped to the chromosomal location 9p21, but are structurally unrelated [Lukas et al., 1995; Zhang et al., 1998]. p16INK4a inhibits cyclinD-Cdk4/6 kinase activities and thus the activation of E2F transcription factors,…”
BackgroundRadulescu, R. T., & Jaques, G. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1902 · Cited by 19
Jiang, H. N., Karnezis, A. N., Tao, M., Guida, P. M., & Zhu, L. (2000) · Oncogene · doi:10.1038/sj.onc.1203722 · Cited by 21
“Induction of p16 caused e cient G1 arrest in U-2 OS cells and this growth suppression was believed to be dependent on endogenous pRB (Koh et al., 1995; Lukas et al., 1995; Medema et al., 1995), which became hypophosphorylated after p16 expression.”
BackgroundConditional transformation of rat embryo fibroblast cells by a cyclin D1-cdk4 fusion gene
Rao, R. N., Stamm, N. B., Otto, K. A., Kovacevic, S., Watkins, S. A., Rutherford, P., Lemke, S., Cocke, K., Beckmann, R. P., Houck, K. A., et al. (1999) · Oncogene · doi:10.1038/sj.onc.1203009 · Cited by 19
“In these cell lines, growth-inhibitory signals from activated Ras led to an increase in the level of p16 (unpublished observations), but these signals are probably overcome by the overexpression of D1-k4 fusion protein (Latham et al., 1996; Lukas et al., 1995; Medema et al., 1995).”
BackgroundLandberg, G. (2002) · Advances in cancer research · doi:10.1016/s0065-230x(02)84002-7 · Cited by 23
Orr, M. S., Reinhold, W. C., Yu, L., Schreiber‐Agus, N., & O'Connor, P. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.7.3803 · Cited by 19
Sang, N., Avantaggiati, M. L., & Giordano, A. (1997) · Journal of Cellular Biochemistry · doi:10.1002/(sici)1097-4644(19970901)66:3<277::aid-jcb1>3.0.co;2-m · Cited by 41
Gene Therapy for Tumors of the Central Nervous System
Chung, R. Y., & Chiocca, E. A. (1998) · Surgical Oncology Clinics of North America · doi:10.1016/s1055-3207(18)30262-x · Cited by 19
Dietz, M. V., van Kooten, J. P., Paats, M. S., Aerts, J. G. J. V., Verhoef, C. K., Madsen, E. V. E., Dubbink, H. J., & von der Thüsen, J. H. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101600 · Cited by 20
Metadata
- Authors
- Lukas, J., Parry, D., Aagaard, L., Mann, D. J., Bartkova, J., Strauss, M., Peters, G., & Bartek, J.
- Affiliations
- Danish Cancer Society (DK)
- ORCID
- Mann, David J.
- Venue
- Nature
- Published
- 1995-06
- Volume
- 375
- Issue
- 6531
- Pages
- 503-506
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2010493387
- Cited by
- 899
- References
- 28
- Citations by year
- 2026: 9 · 2025: 6 · 2024: 6 · 2023: 7 · 2022: 16 · 2021: 15 · 2020: 14 · 2019: 15 · 2018: 17 · 2017: 16 · 2016: 15 · 2015: 15 · 2014: 14 · 2013: 22 · 2012: 16
- FWCI
- 32.15
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Health Sciences › Medicine › Ophthalmology › Ocular Oncology and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Microtubule and mitosis dynamics
- Keywords
- p16, retinoblastoma protein, CDKN2, tumour suppressor, cell cycle arrest, G1 phase progression, D-type cyclins, CDK4, CDK6, retinoblastoma, carcinogenesis, chromosome 9p21
- MeSH terms
- Animals, Carrier Proteins, Cell Cycle, Cells, Cultured, Cloning, Molecular, Escherichia coli, Humans, Mice, Inbred BALB C, Microinjections, Mutation, Proto-Oncogene Proteins, Recombinant Proteins, Tumor Cells, Cultured, Oncogene Proteins, Genes, Tumor Suppressor, Retinoblastoma Protein, G1 Phase, Cyclins, Protein Serine-Threonine Kinases, Cyclin-Dependent Kinases, Cyclin D1, Cyclin-Dependent Kinase Inhibitor p16, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.